Articles

Rosalie Liccardo Pacula is a nationally recognized expert in the economics of substance use and addiction, including opioids, cannabis, and alcohol.

Researcher Neeraj Sood has explored innovative payment models as a strategy for government entities to be able to pay for lifesaving cures that could eradicate diseases like hepatitis C. Louisiana, with some input from Sood, has just implemented a modified version of a subscription model to pay for Hep C treatments.

A mix of universal catastrophic coverage and private insurers would be cheaper than Medicare for All, Dana Goldman wrote in MarketWatch.

Experts from the USC-Brookings Schaeffer Initiative for Health Policy answer commonly asked questions about surprise medical bills and how to deal with them at a policy level.

USC-Brookings Schaeffer Initiative experts provide an analysis of a voluntary vendor approach for Medicare to restrain drug spending for Part B drugs.

As a kidney doctor and health policy researcher, I am surprised that President Donald Trump’s initiative to remake kidney treatment has not gotten more attention. We need to keep paying attention because so much is at stake.

USC-Brookings Schaeffer Initiative researchers review the latest proposed legislation from Representative Ruiz on surprise medical billing.

To lower the Part B portion of drug spending, the Trump Administration has proposed a demonstration project tying Medicare reimbursement for outpatient, physician-administered drugs to international prices. Paul Ginsburg and Steven Lieberman explore the potential consequences of such a rule.

USC-Brookings Schaeffer Initiative researchers explain why we need more primary care physicians and how to close the gap between primary care and specialty medicine.

USC-Brookings Schaeffer Initiative Fellow Christen Young breaks down the Constitutional challenges raised against surprise billing legislation and why they are likely to fail.